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Abstract Metabolic differences among and within tumors can be an important determinant in
cancer treatment outcome. However, methods for determining these differences non-invasively in
vivo is lacking. Using pancreatic ductal adenocarcinoma as a model, we demonstrate that tumor
xenografts with a similar genetic background can be distinguished by their differing rates of the
metabolism of 13C labeled glucose tracers, which can be imaged without hyperpolarization by
using newly developed techniques for noise suppression. Using this method, cancer subtypes that
appeared to have similar metabolic profiles based on steady state metabolic measurement can be
distinguished from each other. The metabolic maps from 13C-glucose imaging localized lactate
production and overall glucose metabolism to different regions of some tumors. Such tumor
heterogeneity would not be not detectable in FDG-PET.
DOI: https://doi.org/10.7554/eLife.46312.001
Introduction
Altered metabolism to sustain rapid growth is one of the hallmarks of cancer (Vander Heiden and
DeBerardinis, 2017). While certain common features of tumor metabolism are retained even in dif-
ferent cancers (Ward and Thompson, 2012; Pavlova and Thompson, 2016), other features can vary
considerably among patients and even within a single tumor (Hensley et al., 2016; Cros et al.,
2018). Since metabolite levels control a host of cellular processes from cell signaling to growth and
differentiation (Vander Heiden and DeBerardinis, 2017; Ward and Thompson, 2012), local varia-
tions in metabolism can impact the sensitivity of the tumor to different forms of treatment. Local
concentrations of glucose (Liu et al., 2017a; Mathews et al., 2014), fatty acids (Svensson et al.,
2016), and amino acids (Mathews et al., 2014), for example, have been shown to influence the
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efficacy of specific types of chemotherapy and radiotherapy, which could lead to a possible change
of treatment strategy (Daemen et al., 2015). Personalizing treatment in response to fluctuations of
metabolites requires a reliable way of measuring the local concentrations of metabolites, which is
less well-established than techniques for measuring the cellular, genomic, and proteomic environ-
ment. The only molecular imaging technique in widespread clinical use, FDG-PET, is largely limited
to measurements of glucose uptake only and cannot characterize downstream biochemical transfor-
mations (Giordano et al., 2016). This limitation is particularly important for organs like the brain
which have a high natural glucose uptake. In these situations, measurements of downstream prod-
ucts like lactate become important in preventing false positives (De Feyter et al., 2018). Other tech-
niques with high specificity, such as MALDI-MS, have been successful at characterizing tumor
metabolic heterogeneity in biopsies (Giordano et al., 2016; Mirnezami et al., 2014) but cannot be
employed in vivo. Tumor metabolism in vivo can be imaged by 1H magnetic resonance spectros-
copy, but as a steady state method it contains contributions from multiple processes and cannot dis-
tinguish the internal metabolism of the tumor from contributions from the surrounding stroma.
Imaging exogenous metabolic tracers offers a more direct way of isolating biochemical pathways.
In principle, this can be accomplished by MRI through the use of 13C labeled tracers. In practice, the
signal from a 13C labeled tracer has been considered too weak for in vivo imaging. Hyperpolarized
MRI was developed to surmount this obstacle, taking advantage of the fact that the high spin polari-
zation of a paramagnetic radical can be transferred to the 13C nucleus on another molecule under
resonant microwave irradiation, increasing the signal by three orders of magnitude or more. How-
ever, this transfer happens efficiently only at temperatures near ~1 K and the hyperpolarization is
rapidly lost when the sample is brought to room temperature before injecting. Due to this limitation,
these studies are normally applied to probes whose 13C T1 relaxation time is long enough that the
enhanced polarization is not lost before the metabolic flux can be determined. Of these probes,
pyruvate has proven to be one of the most useful probes as it interrogates the central switching
point from glycolysis to the TCA cycle (Gray et al., 2014). By comparing the pyruvate-to-lactate con-
version between tumors or between pre- and post-treatment, it has been possible to assess the gly-
colytic profile of tumors in vivo and assess metabolic flux changes during treatment (Gutte et al.,
2015). However, hyperpolarized MRI using pyruvate is unable to detect changes occurring upstream
of the TCA cycle, which are common in many cancers.
An alternative approach that allows a more comprehensive analysis is to use glucose as a meta-
bolic tracer (De Feyter et al., 2018; Rodrigues et al., 2014; Timm et al., 2015). Although glucose
itself is difficult to hyperpolarize, new techniques allow the dynamic imaging of metabolic tracers by
MRI without hyperpolarization. This imaging clearly suffers from low signal sensitivity but this can be
compensated for by efficient noise suppression (Brender et al., 2019). To see how a targeted
approach using hyperpolarized pyruvate compares to the more comprehensive approach offered by
non-hyperpolarized glucose, we analyzed the tumor xenografts of two closely related cell lines with
a similar genetic background in metabolic properties. MIA Paca-2 and Hs 766T are cell lines estab-
lished from pancreatic ductal adenocarcinomas (PDACs) with similar mutations in major metabolic
genes (Deer et al., 2010). However, other differences in the anatomy of the xenografts and in non-
metabolic properties of the cell lines can impact the tumor microenvironment. Hs 766T was derived
from a metastatic site and is expected to have a different stromal boundary compared to MIA Paca-
2, which is derived from a primary heterogeneous tumor. Hs 766T tumor xenografts are more hyp-
oxic than MIA Paca-2 (Zhang et al., 2016), have a more poorly developed vasculature, and was
expected to have a different overall physicochemical environment as a result of this anatomical dif-
ference. While MIA Paca-2 and Hs 766T have similar overall metabolism (Daemen et al., 2015), it is
possible to detect a difference in glucose metabolism using a newly developed technique to image
glycolysis using non-hyperpolarized 13C glucose as a tracer (Brender et al., 2019). Imaging local
metabolite concentrations and biochemistry in this manner may provide a new method for under-
standing the tumor biochemical microenvironment.
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Results
MIA Paca-2 and Hs 766T PDAC xenografts have distinct anatomical and
histological characteristics
Figure 1A and C show transverse slices from the anatomical T2-weighted RARE MRI of xenografts
of Hs 766T and MIA Paca-2. Both tumors are poorly differentiated and show the gross anatomy typi-
cal of Grade 3 PDACs (Matsumoto et al., 2018). While the gross anatomy is similar, the anatomical
microstructure and histology of the two tumors is distinctly different. The MIA Paca-2 tumors appear
entirely homogenous and undifferentiated, an observation that holds down to the cellular level ( Fig-
ure 1.D). By contrast, the homogeneity of the Hs 766T tumors is broken by hypointense spots, a fea-
ture characteristic of focal necrosis ( Figure 1.B) (Jakobsen et al., 1995). As noted in previous
reports (Bailey et al., 2014), we found similar levels of CD31, a common biomarker for angiogenesis
(Figure 1—figure supplement 1), (DeLisser et al., 1997) suggesting immature, rather than defi-
cient, vasculature may be responsible for the higher hypoxia levels in Hs 766T (Bailey et al., 2014).
At the cellular level, cell rupture and inflammation were evident in Hs 766T but not in MIA Paca-2
cells (Figure 1B and D arrows). Despite their overall genetic similarity, the tumor microenvironment
differs and Hs 766T and MIA Paca-2 can be easily distinguished by either anatomical MRI or
histology.
PDAC xenografts can easily be differentiated from non-cancerous host
tissue by metabolic differences
Both the MRI and histology results point to substantial differences in the tumor microenvironment
between the two tumor types that may influence metabolism. Accordingly, we looked for alterations
in central metabolic pathways for biosynthesis, stress response, and energetics that are commonly
modified in tumor cell lines using capillary electrophoresis mass spectrometry (CE-MS) targeted met-
abolic profiling (Matsumoto et al., 2014).
As expected, pancreatic host tissue from the mouse was metabolically distinct from Hs 766T and
MiaPaca2 xenografts (p<0.001 based on two-way ANOVA), with numerous metabolic differences
across multiple metabolic pathways (Figure 1—figure supplement 2). The largest changes are con-
centrated in pathways connected to amino acid biosynthesis and degradation, reflecting an imbal-
ance between amino acid metabolism and protein biosynthesis caused by unsustainable growth.
Amino acid levels of all types and amino acid synthetic intermediates were strongly attenuated in
both cell lines. Both cell lines also show a strong depletion in the level of intermediates throughout
the urea cycle, the primary pathway for protein catabolism, as well as the polyamine biosynthetic
pathway downstream of the urea cycle.
Major metabolic changes are also evident in other pathways. Consistent with previous reports on
PDAC tumors (Ying et al., 2012), steady state concentrations of glycolytic intermediates were ele-
vated in both cell lines, so were the metabolites of the pentose phosphate pathway for nucleotide
and NADPH production (Figure 1—figure supplement 3). To counter the increased oxidative stress,
there were increased levels of metabolites in the methionine redox cycle of the tumor xenografts:
the reduced equivalents are depressed and the oxidized equivalents elevated compared to normal
tissue. Finally, lactate levels are also highly elevated (Wang et al., 2014), consistent with a Warburg
phenotype for both Hs 766T and MIA Paca-2 tumors.
Few metabolic biomarkers distinguish MIA Paca-2 and Hs 766T
The metabolic differences between Hs 766T and MiaPaca2 PDAC tumors were more subtle.
Although it is possible to distinguish between the two types of PDAC tumors using the entirety of
the metabolic profile (p=0.00015 for N = 4, two-way ANOVA with Sidak’s correction for multiple
comparisons), no single pathway stood out as being distinct (Figure 1E). Only a few biomarkers are
distinct at the 5% confidence level with most of the differences that do exist are in the TCA cycle.
The most striking difference was in fumarate levels (p=0.003), which were significantly depressed
(decreased fourfold relative to normal) in MIA Paca-2 and normal or slightly elevated in Hs 766T (ele-
vated 1.4-fold). Fumarate has been suggested as an oncometabolite (Yang et al., 2012;
Sullivan et al., 2013) created both through the TCA cycle and as a byproduct of the urea cycle that
competitively inhibits 2-OG-dependent oxygenases to stabilize the HIF complex and induce
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Figure 1. Distinct anatomical microstructure differences exist between Hs 766T and MIA Paca-2 xenografts while CE-MS shows only subtle metabolic
differences. (A and C) T2 weighted anatomical RARE images of (A) Hs 766T and (C) MIA Paca-2 PDAC xenografts implanted on the left leg. Focal
necrosis is evident in the Hs 766T tumor, but not in the MIA Paca-2 one. (B and D) H and E staining of biopsies from (B) Hs 766T and (D) MIA Paca-2
tumors. Cell rupture is present in the Hs 766T biopsy. (E) Metabolite differences of MIA Paca-2 and Hs 766T PDAC leg xenografts as analyzed by CE/
MS. White boxes indicate metabolites not detected. Gray boxes indicate a statistically insignificant difference between cell lines (two-sided t-test,
corrected for multiple comparisons by the two-stage linear step-up procedure of Holm et al with a confidence level of 5%). Blue and red boxes indicate
statistically significant increases or decreases with respect to MIA Paca-2.
DOI: https://doi.org/10.7554/eLife.46312.002
The following figure supplements are available for figure 1:
Figure supplement 1. Protein expression levels from immunoblotting of tumor extracts of key proteins associated with metabolism.
DOI: https://doi.org/10.7554/eLife.46312.003
Figure supplement 2. Metabolite differences between normal tissue and the MIA Paca-2 PDAC leg xenografts as analyzed by CE/MS.
DOI: https://doi.org/10.7554/eLife.46312.004
Figure supplement 3. Metabolic differences within glycolysis between normal tissue and MIA Paca-2 and Hs 766T PDAC leg xenografts in terms of
absolute concentrations (nmol/g tumor wet weight).
DOI: https://doi.org/10.7554/eLife.46312.005
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pseudohypoxia. Malate and arginosuccinate, two other intermediates linked to fumarate metabolism
were also significantly depressed in MIA Paca-2.
Pyruvate metabolism is indistinguishable between PDAC hypoxic
subtypes
The CE/MS experiment measures the static distribution of metabolites within the tumor, which is the
sum of multiple biochemical pathways. While the data suggests that a difference in glycolysis and
oxidative phosphorylation may exist between the MIA Paca-2 and Hs766 cell lines, the statistical sig-
nificance of these changes is mostly uncertain and the origin of the effect is not clear - it is uncertain
whether the difference is the result of upregulation of specific genes or is a more general effect from
changes in the underlying physiology of the tumor microenvironment. To more directly probe spe-
cific enzyme activities within the glycolytic and TCA cycles, we tracked the in vivo utilization of hyper-
polarized 13C labeled pyruvate using magnetic resonance spectroscopy to detect the de novo
generation of new metabolites from pyruvate. Pyruvate metabolism is a central control point
between glycolysis and oxidative phosphorylation and dysregulation of pyruvate dehydrogenase can
be an important component of the Warburg effect (Saunier et al., 2016).
Figure 2A and B shows typical spectra after the injection of 98 mM solution of hyperpolarized
[1-13C] pyruvate into the tail vein of nude mice bearing MIA Paca-2 or Hs 766T xenografts in the left
leg. The five observed peaks correspond to pyruvate (172.6 ppm), lactate (184.9), alanine (178.2),
bicarbonate (162.6 ppm), and inactive pyruvate hydrate (180.9 ppm). Few differences could be seen
when using C-1 labeled pyruvate as a metabolic tracer; pyruvate metabolism appears to be statisti-
cally indistinguishable in the MIA Paca-2 and Hs 766 T cell lines. The rate of pyruvate to lactate con-
version was similar in MIA Paca-2 and Hs 766T as was both the rate of transamination of pyruvate to
alanine and the first step of the TCA cycle as measured by bicarbonate production (see Figure 2).
While differences in pyruvate metabolism in hypoxic and oxidative tumors have previously been
shown by hyperpolarized C-1 labeled pyruvate (Matsumoto et al., 2018), pyruvate metabolism is
not a sensitive biomarker for distinguishing subtle differences among hypoxic pancreatic adenocarci-
noma subtypes.
Glucose metabolism can be measured in vivo by 13C MRS
The CE/MS data is suggestive of an upregulation in MIA Paca-2 of the later stages of glycolysis rela-
tive to Hs 766T (Figure 1—figure supplement 3), although no single metabolite in the glycolytic
pathway stands out as being statistically different (Figure 1). The CE/MS assay, however, requires a
biopsy, which may be undesirable in some circumstances. To probe glucose metabolism in vivo, a
different technique is needed.
Hyperpolarized glucose imaging has been successfully used to image glycolysis in vivo
(Rodrigues et al., 2014). While glucose is an exemplary tracer from a biological standpoint, its short
relaxation time can be problematic for hyperpolarization (Harada et al., 2010), and the hyperpolari-
zation process places constraints that may be difficult to realize in some situations in a clinical set-
ting. Hyperpolarization of 13C tracers has been considered necessary for imaging and kinetic studies
due to the inherently low signal of 13C MRS. If noise can be reduced to acceptable levels without
hyperpolarization, the restrictions hyperpolarization places on an experiment can be removed. We
have previously shown that it is possible to use the correlation of the 13C signal in both time and
space to reduce the noise level in the signal by an order of magnitude or more without sacrificing
accuracy (Brender et al., 2019). Noise reduction by rank reduction makes it possible to do away
with the hyperpolarization step and the limitations it puts on the metabolic probes that can be used.
Using this technique, we first checked the glucose metabolism of each tumor type following an
injection of 50 mg bolus of [U-13C] glucose using non-localized spectroscopy. The resulting spectra
are complex and include contributions from the a and b anomers of glucose, the natural abundance
13C signal from lipids, as well as signals from downstream metabolites such as lactate and alanine
(Figure 3A). To help resolve these ambiguities, tumors were flash frozen 1 hr after the injection of a
[U-13C] glucose bolus and the polar fraction analyzed by multidimensional NMR. Strong signals at
22.8 and 18.9 ppm in the indirect dimension of the HSQC spectrum (Figure 3—figure supplement
1A) and carbon satellites in the TOCSY spectrum (Lane and Fan, 2007) (Figure 3—figure supple-
ment 1B) confirmed that the peaks at 22.8 ppm and 18.9 ppm arise from 13C labeled lactate and
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alanine, respectively (Figure 3A). 13C labeled glutamate and aspartate are detectable in the ex vivo
HSQC but not in the in vivo MRS, likely because the longer relaxation times (Badar-Goffer et al.,
1990; Allouche-Arnon et al., 2013) strongly attenuate the signal with the short recycle delay used
in the in vivo experiment. The peaks at 95 and 98 ppm can potentially arise from carbon 1 of the a
and b anomers of either glucose or glucose-6-phosphate. The absence of any detectable peaks near
75 ppm confirms they arise exclusively from glucose without contribution from glucose-6-phosphate
Figure 2. Pyruvate metabolism is similar in Hs 766T and MIA Paca-2 Xenografts. (A and B) Representative signal
after injecting 300 mL of 98 mM hyperpolarized [1-13C] pyruvate into the tail vein of a mouse of a nude mouse with
either a (A) Hs 766T or (B) MiaPaCa2 leg xenograft. Signal loss is due to a combination of the loss of
hyperpolarization and conversion of pyruvate to other metabolites. Corresponding kinetic traces of the pyruvate,
lactate, alanine and bicarbonate signals metabolites for (C) Hs 766T and (D) MiaPaCa2 xenografts. (E) Ratio of the
integrated lactate and pyruvate for Hs 766T (n = 18) and MiaPaca2 (n = 22) mice. The ratio is equal to the net
lactate to pyruvate conversion rate in the absence of lactate efflux or back conversion. (F) Decay rate of the
pyruvate signal, equivalent to the sum of the net lactate to pyruvate conversion rate and the effective relaxation
rate (T1eff, assumed to be the same between cell lines). (G and H) Ratio of the integrated alanine (G) or
bicarbonate (H) to pyruvate. No statistically significant difference between cell lines was detected for any measure
(Mann-Whitney rank test). Error bars represent 95% confidence intervals.
DOI: https://doi.org/10.7554/eLife.46312.006
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Figure 3. Glucose metabolism differentiates Hs 766T and MiaPaca2 xenografts. (A) Representative signal before
and 1 hr after injecting 50 mg of [U-13C] glucose into the tail vein of a mouse of a nude mouse with a MIA Paca-2
leg xenograft. The largest signal at 32 ppm is due to endogenous lipids, while glucose peaks can be seen in
region from 60 to 100 ppm and lactate and alanine peaks can be detected at 22.8 ppm and 18.9 ppm,
respectively. (B) Representative signals before and after rank reduction by SVD to reduce noise. No
hyperpolarization is used in this experiment; the time dependence of the signal is due to metabolic
Figure 3 continued on next page
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or any other glycolytic intermediates (Timm et al., 2015; Wishart et al., 2018; Wishart et al.,
2007). While the peaks at 95 and 98 ppm can be definitively assigned to carbon 1 of glucose, the
HSQC and the pre-injection spectra (Figure 3A) confirms the other intense peak at 63 ppm and the
spectrally crowded region between 63 and 78 ppm contains contributions from glycerol containing
species. The lack of 13C-13C couplings for the glycerol resonances in the HSQC show that these mol-
ecules were not derived directly from the glucose bolus.
The peak at 98 ppm was therefore used as a marker as it can be assigned specifically in this case
to glucose and not any other molecule. Specifically, an increase in the intensity of the 98 ppm reso-
nance reflects the arrival of glucose from the bloodstream into the instrument’s field of view (gluco-
neogenesis within the tumor is assumed to be negligible on this time scale). A decrease in intensity
reflects either the removal of glucose by the bloodstream out of the field of view or the conversion
of glucose into other species. Similarly, the appearance of peaks at 22.8 and 18.9 ppm reflect the
conversion of lactate and alanine, respectively, and/or the arrival of circulating lactate or alanine pro-
duced from 13C glucose outside the tumor (Hui et al., 2017; Faubert et al., 2017).
Glucose metabolism, but not glucose uptake, distinguishes PDAC
hypoxic subtypes
The improvement in temporal resolution afforded by the greatly increased signal-to-noise ratio
allows an assessment of the fast glucose import step by MRI. The kinetics of glucose import have
not been resolved effectively by 13C MRI previously and are difficult to measure even with PET imag-
ing (Kuntner, 2014). No statistically significant difference between cell lines could be detected in
the rate of glucose uptake (Figure 3D), in agreement with the similar levels of the glucose trans-
porter GLUT1, detected by western blot (see Figure 1—figure supplement 1), or in the rate of lac-
tate formation (Figure 3G). The rate of glucose metabolism after import; on the other hand,
distinguishes MIA Paca-2 and Hs 766T xenografts. Hs 766T xenografts displayed a statistically signifi-
cant slower glucose metabolism than MIA Paca-2 xenografts (Figure 3E, Mann-Whitney rank test,
p=0.02, Cohen’s d = 3.43, large effect size). This difference is also reflected in the time-averaged
glucose to lactate ratio (Figure 3F, Mann-Whitney rank test, p=0.03, Cohen’s d = 1.20, large effect
size), which is an approximate measure of the relative rates of the appearance of lactate and disap-
pearance of glucose within the FOV of the scanner (Hill et al., 2013). To confirm the presence of a
metabolic difference, the glucose, lactate, and glutamate peaks of the HSQC spectra from the polar
extracts of MIA Paca-2 and Hs 766T tumors were quantified (Figure 3H). As expected, the metabo-
lite ratios from ex vivo NMR do not exactly match those observed in the in vivo MRS technique
because of the strong bias toward fast relaxing species such as glucose in the MRS spectrum due to
the short repetition time. Nevertheless, the predicted trend (higher lactate to glucose ratios in MIA
Paca-2) is similar in both experiments.
Glucose imaging by 13C MRS detects local differences in metabolism
within PDAC tumors
Figure 1E shows that a metabolomic profile from a CE/MS can distinguish between xenografts of
the MIA Paca-2 and Hs 766 T cell lines. Unfortunately, mass spectrometry can only be done ex situ
and it is impossible to apply in a living tumor. The MRI spectroscopy experiment in Figure 3 can
Figure 3 continued
interconversion. Spectra were acquired every 16 s (16 averages per scan). (C) Representative kinetic traces for the
glucose signal at 98 ppm for Hs 766T (n = 10) and MIA Paca-2 (n = 11) xenografts. (D–F) Whether expressed as
directly as rate obtained from curve-fitting (E) or as a ratio (F), a statistically significant difference in the rate of
glucose metabolism can be seen between the Hs 766T or MIA Paca-2 PANC subtypes (Mann Whitney rank test,
p=0.05 and 0.03 respectively). No statistically significant difference could be seen in the rate of glucose uptake (D)
or lactate production (G). (H) Ex vivo NMR analysis of glucose and glucose-derived metabolites in the polar extract
of the tumor xenografts (n = 5 for each group). Error bars in all cases represent 95% confidence intervals.
DOI: https://doi.org/10.7554/eLife.46312.007
The following figure supplement is available for figure 3:
Figure supplement 1. Ex vivo NMR analysis of Hs766T and MIA Paca-2 xenografts.
DOI: https://doi.org/10.7554/eLife.46312.008
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efficiently differentiate between MIA Paca-2 and Hs 766T xenografts but does not give information
on local variations within the tumor. The low rank reconstruction procedure used in Figure 3 can be
extended into higher dimensions for imaging by tensor decomposition to give 30-fold or higher
increases in signal to noise in spectroscopic imaging. As a first test, we used chemical shift imaging
to provide a low-resolution (3  316 mm) map of the rates of glycolysis and anaerobic fermenta-
tion (Figure 4A–D). Simple chemical shift imaging was used to minimize potential imaging artifacts;
considerable acceleration can be achieved by a more efficient pulse sequences and is the focus of
ongoing research.
Figure 4 shows representative results from chemical shift imaging of MIA Paca-2 and Hs 766T
xenografts before and after noise suppression (see Materials and methods). While the raw images
are almost entirely noise, (Figure 4A and E) the processed images by tensor decomposition clearly
show localized uptake of glucose within the tumor and conversion to lactate. As in the non-localized
Figure 4. CSI imaging of a Hs 766T mouse leg xenograft after a 50 mg [U-13C] glucose injection in a volume of 300 microliters of PBS. An 8  8 image
of the tumor bearing mouse leg was acquired by chemical shift imaging every 48 s for 60 min. The final image was zero-filled to 16  16. Each is voxel
0.15 cm x 0.15 cm x 1.6 cm in size. (A) The glucose region of the spectra at 12 min overlaid on the anatomical image. (B) Same image after tensor
factorization. (C and D) Rate map of (C) glucose and (D) lactate metabolism calculated from the image series (E and F). Signal from the voxel indicated
by the white dashed line (E) before and (F) after tensor factorization. (G) Contour maps created from the peak maximums of the glucose and lactate
signals at the time points indicated.
DOI: https://doi.org/10.7554/eLife.46312.009
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experiment, the glucose signal can be seen to decay and the corresponding lactate signal at 23 ppm
to simultaneously increase as the tumor metabolized the bolus (Figure 4G). Local differences in
metabolism can be detected in many tumors. For example, in one Hs 766T xenograft (Figure 4G)
glucose metabolism is distributed relatively uniformly after taking into account the overall tumor
anatomy. Lactate production, on the other hand, is localized in this tumor to one side where focal
necrosis is more evident. In comparable MIA Paca-2 tumors (Figure 5), glucose uptake and lactate
production appear to be more tightly correlated, congruent with the greater homogeneity apparent
in the anatomical MRIs.
Discussion
Pancreatic ductal adenocarcinoma (PDAC) represent 90% of pancreatic cancers and are character-
ized by a poor prognosis and limited treatment strategies (Hidalgo, 2010; Garrido-Laguna and
Hidalgo, 2015). Given PDACs resistance to traditional chemo- and radiotherapy regimes
(Adamska et al., 2017), alternative points of attack are being considered. One potential point of
attack is the dysregulated metabolism of PDACs (Blum and Kloog, 2014), which is highly dependent
on protein autophagy and catabolism (Yang et al., 2011; Kamphorst et al., 2015) and exogenous
glutamine and glucose (Ying et al., 2012; Biancur et al., 2017). Further, PDAC tumors usually have
alterations in the activity in the urea cycle to support pyrimidine and amino acid synthesis
(Rabinovich et al., 2015; Liu et al., 2017b) and often display a Warburg phenotype of increased
glycolysis followed by diversion to lactate (Anderson et al., 2017). Each alteration and dependency
represents a potential point of intervention. Although targeting the master genetic switches for
these transformations, p53 and kRAS, (Ying et al., 2012; Bryant et al., 2014) is difficult, the down-
stream enzymes are practical targets. Inhibitors for lactate dehydrogenase (Rai et al., 2017) and the
lactate transporter MCT1 (Sonveaux et al., 2008) have shown promise in preclinical trials and may
enter clinical trials in the near future. Beyond the Warburg effect, researchers have begun to target
other vulnerable aspects of PDAC metabolism such as amino acid synthesis (Ananieva, 2015) or the
unique chemical environment of tumors by hypoxia activated prodrugs (Bailey et al., 2014;
Liu et al., 2012).
Targeting aberrant metabolism requires a method of monitoring treatment progress and select-
ing suitable patient populations. Response to cancer treatment can be highly variable and there is a
concerted push to tailor treatment regimens to individual patients (Jain, 2005). For protein targets
such as receptors, genome sequencing or protein expression profiling is often sufficient to demon-
strate a patient has a vulnerable mutation. Targeting aberrant metabolism is more difficult as the
Figure 5. Contour maps created from time averages of the peak maxia of the glucose and lactate signals for three representative MIA Paca-2 (left) and
Hs 766T (right) tumors.
DOI: https://doi.org/10.7554/eLife.46312.010
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metabolism of tumors is not limited to the tumor itself, but also contains substantial contributions
from the surrounding cells both directly through diffusion of metabolites across the tumor boundary
(Sousa et al., 2016) and indirectly through the influence of regulatory and epigenetic signals
(Sherman et al., 2017). The physical microenvironment of the tumor can also affect metabolism.
Deficient or improperly formed (Bailey et al., 2014) vasculature often induces hypoxia in PDAC
tumors (Koong et al., 2000) which can induce metabolic changes (Matsumoto et al., 2014;
Guillaumond et al., 2013) that would not be evident by genetic analysis alone.
Methods for determining the internal metabolism of tumors non-invasively in vivo are lacking and
represent a critical obstacle for the development of targeted metabolic therapy. The steady state
metabolism of PDAC tumors can be probed indirectly through analysis of urine, blood, or pancreatic
cyst fluid (McGranaghan et al., 2016) or more directly through magnetic resonance spectroscopy.
However, metabolic networks are more flexible than protein networks and flux through the network
can be rerouted to limit the impact of targeted enzymes (Biancur et al., 2017). Evaluating the target
engagement of potential inhibitors can be difficult under these conditions. We demonstrate the
potential of multimodal metabolic profiling of PDAC tumors for distinguishing xenograft tumors that
are genetically similar but display very different metabolic phenotypes. Hs 766T is a cell line derived
from lymphatic metastasis of pancreatic cancer that generates highly necrotic, hypoxic, slow growing
heterogenous tumors. MIA Paca-2 is derived from primary cancer whose tumors are less necrotic,
grow faster, and are highly homogenous. Despite their dissimilar origin and physiological differen-
ces, the steady state metabolism probed by CE/MS of Hs 766T and MIA Paca-2 is markedly similar,
with only a few potential differentiating biomarkers (Figure 1E). Hyperpolarized pyruvate-lactate
fluxes of Hs 766T and MIA Paca-2 xenografts estimated by 13C hyperpolarized pyruvate MRI were
statistically indistinguishable (Figure 3). The flux through the TCA cycle and anaerobic fermentation
is similar, as expected from the presence of KRAS and TP53 mutations in both cell lines and similar
LDHA levels (Figure 1—figure supplement 1). Hyperpolarized MRI of pyruvate, while it has proven
clinically useful in other circumstances (Gutte et al., 2015), did not provide sufficient information for
metabolic discrimination in this instance.
The use of [U-13C] glucose instead of [1-13C] pyruvate in this study allowed for a more compre-
hensive overview of metabolism. Measurements of in vivo glucose metabolism by 13C MRI have
proved difficult because of difficulty of hyperpolarizing glucose and the low SNR in non-hyperpolar-
ized experiments. The approximately 30 fold improvement in SNR from low rank tensor decomposi-
tion (Figure 4E) allows the difficult hyperpolarization step to be avoided (Brender et al., 2019),
eliminating some of the practical barriers to clinical implementation of 13C metabolic imaging. The
most important information acquired by this method is the direct measurement of rates of glycolysis
and lactate fermentation, allowing imaging of the Warburg effect. High glucose uptake is one of the
most well studied features of cancer and has been utilized in FDG-PET imaging in clinical settings.
FDG-PET is limited in that the radiotracer cannot differentiate the metabolic conversions that occur
beyond glucose uptake and phosphorylation. In contrast to FDG-PET, investigation of [U-13C] glu-
cose metabolism by 13C MRI can potentially probe more diverse and subtle metabolic differences in
tumors. We observed one such metabolic difference in Figure 3; among Hs 766T and MIA Paca-2
PDAC xenograft animal models, glucose uptake was similar while glucose metabolism was distinct.
Our findings suggest some advantages for 13C glucose imaging. Compared to FDG-PET, there is
no need for a radioactive tracer, which makes this imaging potentially safer and less invasive. By
observing the lactate production at later time points, 13C glucose imaging can potentially detect
cancer even in highly glucose-consuming tissue such as brain or liver. It can also potentially detect
cancer in the bladder because glucose is not excreted immediately in urine, while FDG excreted in
the urinary tract and excess signal in the bladder can interfere with lesion detection within or near
the bladder wall. In contrast to hyperpolarized MRI, non-hyperpolarized 13C glucose imaging does
not require onsite preparation of the probe, removing one of the main barriers to clinical translation
of metabolic imaging by MRI.
Balancing these potential advantages, there are some limitations that should be acknowledged.
The technique is inherently insensitive and requires the delivery of a large bolus that likely changes
the initial metabolic state. The results therefore reflect the metabolism under a specific perturbation
and should not be interpreted as reflective of the basal metabolic state. While this difference is likely
less important in using metabolism as a biomarker, caution should be exercised in interpreting the
results as reflective of the normal metabolism of the tissue. Other techniques, such as hyperpolarized
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13C MRI, may be more useful in this context. The power of the low rank denoising technique scales
as the square root of the number of acquisitions. As such, short repetition times are advantageous.
The short repetition time skews the intensity towards metabolites with short T1 relaxation times.
While the rates of conversion are not affected by this skew, the apparent concentrations are, and
the relative intensities should not be used as a measure of relative concentration. While some chal-
lenges remain and the technique is inferior to PET in some respects, particularly with respect to reso-
lution and imaging time, 13C glucose imaging by MRI may emerge as a viable adjunct or alternative
to FDG-PET in evaluation of patients with known or suspected cancer.
Materials and methods
Mouse models
The animal experiments were conducted according to a protocol approved by the Animal Research
Advisory Committee of the NIH (RBB-159-2SA) in accordance with the National Institutes of Health
Guidelines for Animal Research. Female athymic nude mice weighing approximately 26 g were sup-
plied by the Frederick Cancer Research Center, Animal Production (Frederick, MD) and housed with
ad libitum access to NIH Rodent Diet #31 Open Formula (Envigo) and water on a 12 hr light/dark
cycle. Xenografts were generated by the subcutaneous injection of 3  106 MIA PaCa-2 (America
Type Cell Collection (ATCC), Manassas, VA) or Hs 766T (Threshold Pharmaceuticals, Redwood City,
CA) pancreatic ductal adenocarcinoma cells. (Kim et al., 2009) Both cell lines were tested in May
2013 and authenticated by IDEXX RADIL (Columbia, MO) using a panel of microsatellite markers.
Molecular testing of cell lines for multiple pathogens, including mycoplasma, was performed at the
time of receipt and prior to in vivo studies. All cell lines were maintained in RPMI 1640 supple-
mented with 10% fetal calf serum and antibiotics.
CE/MS analysis
Tumors were excised when the volume reached 600 mm3 and immediately frozen in liquid nitrogen
and stored at  80˚C until analysis. A total of 116 metabolites involved in glycolysis, the pentose
phosphate pathway, the tricarboxylic acid cycle, the urea cycle, and polyamine, creatine, purine, glu-
tathione, nicotinamide, choline, and amino acid metabolism were analyzed using CE-TOF and QqQ
mass spectrometry (Carcinoscope Package, Human Metabolome Technologies, Inc). Statistical signif-
icance was established by multiple two-sided t-tests, corrected for multiple comparisons by the two-
stage linear step-up procedure of Holm et al with a confidence level of 5% (Holm, 1979;
Seaman et al., 1991).
Western blotting analysis
The mice bearing MIA Paca-2 and Hs 766T tumors (n = 4 for each group) were euthanized by breath-
ing carbon dioxide gas, and tumor biopsy samples were excised. The tumor tissues were immedi-
ately homogenized with T-PER tissue protein extraction reagent (Thermo scientific). The
homogenate was centrifuged, and the supernatant was used for western blot analysis. Hexokinase-2,
Glut-1, LDHA proteins in tumor extract were separated on 4% to 20% Tris-Glycine gel and CD31
was separated on NuPAGE 3% to 8% Tris-Acetate gel (Life Technologies) by SDS-PAGE and were
transferred to nitrocellulose membrane. The membranes were blocked for 1 hr in blocking buffer
(3% nonfat dry milk in 0.1% Tween 20/TBS), which was then replaced by the primary antibody
(1:500-1:1000), diluted in blocking buffer, and then incubated for 1 hr at room temperature. The
membranes were then washed three times in washing buffer (0.1% Tween 20/TBS). The primary anti-
body was detected using horseradish peroxidase–linked goat anti-mouse or goat anti-rabbit IgG
antibody at a 1:2000 dilution (Santa Cruz Biotechnology), visualized with Western Lightning Plus-ECL
enhanced chemiluminescence substrate (Perkin Elmer Inc) and measured by the Fluor Chem HD2
chemiluminescent imaging system (Alpha Innotech Corp.). Density values for each protein were nor-
malized to actin or HSC70.
Hyperpolarized 13C MRS experiments
Samples for NMR were prepared and analyzed as previously described in Brender et al. (2019)
[1-13C] pyruvic acid (30 mL), containing 15 mM TAM and 2.5 mM gadolinium chelate ProHance
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(Bracco Diagnostics, Milano, Italy), was hyperpolarized at 3.35 T and 1.4 K using the Hypersense
DNP polarizer (Oxford Instruments, Abingdon, UK) according to the manufacturer’s instructions.
Typical polarization efficiencies were around 20%. After 40–60 min, the hyperpolarized sample was
rapidly dissolved in 4.5 mL of a superheated HEPES based alkaline buffer. The dissolution buffer was
neutralized with NaOH to pH 7.4. The hyperpolarized [1-13C] pyruvate solution (96 mM) was intrave-
nously injected through a catheter placed in the tail vein of the mouse (1.1 mmol/kg body weight).
Hyperpolarized 13C MRI studies were performed on a 3 T scanner (MR Solutions, Guildford, UK)
using a home-built 13C solenoid leg coil. After rapidly injecting the hyperpolarized [1-13C] pyruvate,
spectra were acquired every second for 240 s using a single pulse acquire sequence with a sweep
width of 3.3 kHz and 256 FID points.
Dynamic 13C glucose MRS without hyperpolarization
The magnetic resonance spectroscopy experiments were performed on a 9.4 T Biospec 94/30 hori-
zontal scanner using a 16 mm double resonance 1H/13C coil constructed as described in
Brender et al. (2019). Each mouse was anesthetized during imaging with isoflurane 1.5–2.0%
administered as a gaseous mixture of 70% N2 and 30% O2 and kept warm using a circulating hot
water bath. Both respiration and temperature were monitored continuously through the experiment
and the degree of anesthesia adjusted to keep respiration and body temperature within a normal
physiological range of 35–37˚ C and 60–90 breaths per min. Before the start of the experiment, ana-
tomical images were acquired with a RARE fast spin echo sequence (Hennig et al., 1986) with 15
256  256 slices of 24 mm 24 mm  1 mm size with eight echoes per acquisition, a 3 s repetition
time, and an effective sweep width of 50,000 Hz. Samples were shimmed to 20 Hz T with first and
second order shims using the FASTMAP procedure (Gruetter, 1993).
[U-13C] Glucose was administered as a 50 mg bolus injected into the tail vein immediately prior to
the start of the experiment. Immediately after the injection, non-localized spectra were acquired
with the NSPECT pulse-acquire sequence using maximum receiver gain, a repetition time of 50 ms,
Ernst Angle excitation of 12˚, 256 FID points, a sweep width of 198.6 ppm, 16 averages per scan,
and 4500 scans for a total acquisition time of 1 hr. MLEV16 decoupling (Levitt et al., 1983;
Levitt et al., 1982) was applied during acquisition using  20 dB of decoupling power and a 0.2 ms
decoupling element. The decoupling pulse was centered on the main proton lipid resonance at 1.3
ppm. Chemical shift imaging experiments were performed similarly except an 8  8 image using 0.3
cm x 0.3 cm x 1.5 cm voxels was acquired every 48 s (16 averages per scan) for 90 min using rectilin-
ear phase encoding.
Signal processing
Signal processing was performed as described in Brender et al. (2019). For non-localized (two
dimensional) experiments, the first 67 points of the FID in the time dimension were removed to elim-
inate the distortion from the 13 ms dead time of the Bruker 9.4 T. (Cobas, 2008). The FID was Four-
ier transformed and the phase estimated by the entropy minimization method of Chen et al. (2002)
as implemented in MatNMR (van Beek, 2007). After low rank reconstruction by SVD (see below),
the baseline was estimated by a modification of the Dietrich first derivative method to generate a
binary mask of baseline points (Dietrich et al., 1991), followed by spline interpolation using the
Whittaker smoother (Eilers, 2003) to generate a smooth baseline curve (Cobas et al., 2006). The
final correction adjusts for the limited number of points in the frequency dimension by continuation
of the FID by linear prediction. The remaining 189 points of the FID after truncation in the first step
were extrapolated to 1024 points using the ‘forward-backward’ linear prediction method of Zhu and
Bax (1992). Fourier transforming the FID of the transients from each voxel individually generated
the final spectrum. Phase estimation proved difficult for to the chemical shift imaging experiments
and therefore the spectra for chemical shift imaging experiments are shown in magnitude mode.
Low rank reconstruction
For the two-dimensional signal matrices generated by non-localized pulse acquire experiments, the
rank reduced signal was generated by truncating the SVD by setting the N-r diagonal values of the
singular value matrix S to 0, where N is the number of rows in S and r is the predicted rank. The pre-
dicted rank was set to five unless otherwise specified. Tensor decomposition was achieved through
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higher order orthogonal iteration (De Lathauwer et al., 2000) in the Matlab NWay package
(Andersson and Bro, 2000) using a rank of 8 in the temporal and spectral dimensions and six in
each spatial dimension.
Kinetic modeling
Glucose kinetics were analyzed by piecewise analysis of the signal from glucose carbon-1 at 98 ppm
(Zierhut et al., 2010). The signal at initial time points (t0 <5 m) can be described by a single, empiri-
cally based exponential transport function (Chiang et al., 2017) describing the combined effects of
perfusion and import:
S98 ppm tð Þ ¼ S98;total 1 Be
 ktranst
  
; t0 (1)
Assuming negligible gluconeogenesis during the experiment, the kinetics after the complete pas-
sage of the bolus (t > 5t0=25 m) can be approximated as a decay from multiple first order pathways:
dS98 ppm
dt
¼ 
i
X
ki; t>5t0 (2)
which has the simple solution:
S98 ppm tð Þ ¼ S98;total e
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A
; t>5t0 (3)
where ki includes terms from both metabolic conversion and clearance of glucose from the tumor.
Since the system is not closed, the terms do not balance - the loss in glucose is not necessarily
equal to the total change in the concentration of downstream metabolites because of clearance of
glucose and other metabolites from the tumor. As such, it is difficult to evaluate the individual terms
in Equation 3 . We therefore report the sum
i
X
ki as the rate of glucose ’utilization’, which we define
as the time dependent change in glucose concentration in the field of view. Lactate kinetics are han-
dled similarly except there is no transport term and the signal is evaluated at 23 ppm. Lactate ’for-
mation’ similarly refers to the time-dependent change in lactate concentration in the field of view
and may reflect contributions from circulating 13C-labeled lactate created outside the tumor
(Hui et al., 2017; Faubert et al., 2017).
The kinetics of pyruvate metabolism in the hyperpolarized MRS experiment were evaluated by
integrating the rate equations as described in Daniels et al. (2016). For simplicity, a two-pool unidi-
rectional flux model was assumed with equal relaxation times for lactate and pyruvate. The concen-
tration of 13C labeled lactate at the initial time point was also assumed to be zero. Making these
assumptions, the final equations are:
Pyr tð Þ ¼
Pyr 0ð Þ
k
e  kþ
1
T1ð Þt
 
; t0 (4)
Lac tð Þ ¼
Pyr 0ð Þ
k
e 
1
T1ð Þt   e  kþ
1
T1ð Þt
 
; t0 (5)
Ex vivo NMR analysis
50 mg of 13C-labeled glucose was injected intravenously through the tail vein to start the labeling
experiment. Mice were sacrificed by cervical dislocation one hour after injection, following an intra-
venous saline flush to reduce paramagnetic relaxation from heme contamination from the blood.
The tumor was then removed and snap frozen in liquid nitrogen and then stored at  80˚C until the
extraction procedure.
The polar fractions were isolated from the frozen tumor sections using a modification of a previ-
ously published procedure for cell extracts (Crooks et al., 2019). Briefly, a section of the frozen
tumor was cut and then pulverized in liquid nitrogen using a cryogenic grinder (Freezer/Mill 6875,
Spex SamplePrep). Approximately 50 mg of the ground tissue powder was weighed and then imme-
diately quenched with 2 ml of acetonitrile at  20˚C. The solution was allowed to thaw on ice and 1.5
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ml of ice cold dd H2O was added to the thawed extract. Lipids and non-polar metabolites were
extracted by the addition of 1 ml of  20˚C chloroform with vigorous mixing. Addition of chloroform
creates a three-phase system consisting of the polar and nonpolar fractions and an interphase layer
consisting primarily of proteins. Following centrifugation at 6400 g for 30 min, 90% of the aqueous
phase was transferred to a pre-tared microcentrifuge tube. After removal of the non-polar chloro-
form phase, the interphase layer was washed with ice cold 2:1 choloroform/methanol containing 1
mM BHT and recentrifuged. The aqueous phases were then combined and lyophilized. To remove
residual proteins, the lyophilized powder was reconstituted in 100 mL of ice cold dd H2O followed by
400 mL of ice cold acetone. Samples were then incubated at  80˚C for 30 min to facilitate protein
precipitation. The protein precipitate was isolated by centrifugation for 30 min at 14,000 rpm. The
pellet was then washed with 100 mL of 60% acetonitrile and the remaining supernatant after centrifu-
gation re-lyophilized.
NMR samples were prepared by dissolving the lyophilized powder in D2O containing DSS-d6 as
reference and concentration standard. For each sample, a 1D 1H Presat and 1D 1H-13C HSQC spec-
tra were recorded at 15˚C on a 16.45 T Bruker Avance III spectrometer using a 1.7 mm inverse triple
resonance cryoprobe with an acquisition time of 2 s and a relaxation delay of 4 s for the Presat
experiment, and an acquisition time of 0.2 s and relaxation delay of 1.8 s for the HSQC experiments
with adiabatic 13C decoupling. The strongest sample from each group was also analyzed by high-res-
olution 2D multiplicity-edited HSQC and TOCSY (50 ms mixing time). TOCSY and high-resolution
multiplicity-edited 1H-{13C}-HSQC spectra were recorded at 14.1 T on an Agilent DD2 spectrometer
using a 3 mm inverse triple resonance cold probe, with an acquisition time in t2 of 1 s and a relaxa-
tion delay of 1 s and an isotropic mixing time of 50 ms (TOCSY) and an acquisition time of 0.2 s in t2,
recycle time of 2 s with 600 complex increments in t1 for HSQC to resolve
13C-13C couplings in F1
(Fan and Lane, 2016).
Spectra were transformed, apodized using a cosine- squared function and 1 Hz line broadening
exponential, phased and baseline corrected using the MNOVA software. Spectra were assigned
using in-house data bases (Fan and Lane, 2013) and those of the HMDB (Wishart et al., 2018;
Wishart et al., 2007) as previously described. 2D spectra were zero filled to 16384  2048 complex
points (TOCSY), and 8192  4096 complex points (HSQC), transformed and apodized with a 1 Hz
line broadening exponential and a cosine-squared function.
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